Exosome-based therapeutics India gets boost with Pandorum–Nucelion pact

Pandorum Technologies partners Nucelion Therapeutics to expand exosome-based therapeutics India manufacturing and supply across the APAC region

Bengaluru-based clinical-stage regenerative medicine company Pandorum Technologies has entered into a strategic collaboration with Nucelion Therapeutics, the contract research, development and manufacturing organisation (CRDMO) arm of Bharat Biotech. The partnership aims to expand manufacturing capacity for Pandorum’s advanced biologics platform across the Asia-Pacific (APAC) region.

Through this agreement, Pandorum will leverage Nucelion’s infrastructure to scale production of its pipeline of exosome-based therapeutics India is increasingly gaining global attention for. The collaboration is also expected to enhance regulatory readiness and ensure reliable regional supply as programmes move closer to clinical and commercial milestones.

Focus on ocular and inflammatory diseases

Pandorum’s current clinical programmes are focused on addressing serious ocular conditions such as ocular surface injury and inflammatory corneal diseases. These include Stevens–Johnson syndrome (SJS) and neurotrophic keratitis, which currently have limited treatment options.

The company’s proprietary platform is designed to deliver disease-modifying outcomes, positioning exosome-based therapeutics India as a promising approach for tackling complex inflammatory and degenerative disorders. By combining biological precision with scalable manufacturing, Pandorum aims to improve long-term patient outcomes.

Expansion into multi-organ regenerative therapies

Beyond ophthalmology, Pandorum plans to expand its pipeline into therapies targeting degenerative changes in the skin, lungs, and other organ systems. These conditions are often driven by chronic inflammation, vascular abnormalities, and fibrosis.

Such ambitions underline the growing relevance of exosome-based therapeutics India in regenerative medicine, as researchers explore their potential to reverse tissue damage rather than merely manage symptoms.

Government support and Make in India signal

Dr Jitendra Kumar, Managing Director of BIRAC under the Department of Biotechnology, Government of India, said the collaboration sends a strong message about India’s readiness to innovate and manufacture advanced therapeutics for global markets. He noted that the partnership reflects the success of “Innovate and Make in India” in addressing unmet medical needs worldwide.

Manufacturing scale and quality focus

Nucelion Therapeutics’ Chief Business Officer Dr Raghu Malapaka said the company’s advanced manufacturing platforms and quality systems are built to support complex biologics at scale. These capabilities will enable consistent production of Pandorum’s designer assets, including Kuragenx, an investigational therapy with the potential to redefine ocular disease treatment across APAC.

Pandorum CEO Dr Tuhin Bhowmick said building a globally scalable regenerative medicine platform requires strong regional manufacturing partners. With this collaboration, exosome-based therapeutics India is positioned to reach patients across APAC and beyond through high-quality, reliable production.